Canada: The Top 5 Trends In Canadian Intellectual Property Law For 2015

Last year promised significant changes in Canadian IP law; some of which will be realized in 2015. As the first quarter draws to a close, this year's trends in IP law are emerging. Canada's international trade negotiations will have a major impact on trademark, copyright and patent law. The focus on the interaction between competition law and intellectual property settlement agreements is sharpening. Pharmaceutical litigation is entering a new, biological age. Drug prices, ever an issue in Canada, may face heightened scrutiny. We see the following as the top five emerging trends.

1. Trade-driven Changes to Trademarks Practice

In response to Canada's trade negotiations with the European Union, the Federal Government introduced major changes to Canada's Trade-marks Act. These amendments are expected to come into force in late 2015 or early 2016. Among these amendments, the most important is likely to be the removal of the requirement in a trademark application that the applicant state whether its mark has been used in Canada, or whether the use is proposed. The amendments will not eliminate the requirement that a trademark be used to maintain a registration, but the change is nevertheless dramatic. We anticipate that trademark owners will need to ramp up their policing efforts and we may see an increase in opposition and cancellation proceedings to clear the path of marks that are not in fact in use.

These changes follow amendments to the Trade-marks Act, Copyright Act and Customs Act to create new border enforcement measures to help combat the importation or exportation of counterfeit goods into or out of Canada. Enacted through the Combating Counterfeit Products Act (CCPA), these amendments are intended to fulfill Canada's obligations under the Canada-Korea Free Trade Agreement. The CCPA introduced a Request for Assistance program that allows copyright and trademark owners to formally request the assistance of the Canada Border Services Agency in enforcing their rights. The use of this program is a trend to watch.

2. Others Have Taken Notice: Copyright's Notice and Notice Regime

To discourage online copyright infringement, a notice and notice regime came into force on January 2, 2015, under the Copyright Act. This regime allows copyright owners to send notices of alleged copyright infringement to Internet users through Internet Service Providers (ISPs) and website hosts. This regime is considerably different from its American counterpart, the notice and takedown system. Under the American Digital Millennium Copyright Act, an online service provider must remove or disable access to the allegedly infringing material. The gentler, Canadian approach does not require ISPs, website hosts or search engine providers to remove infringing content.

This limitation has not gone unnoticed by the International Intellectual Property Allowance (IIPA). The IIPA is a private sector coalition that submits reports to the U.S. Trade Representative, including the Special 301 Report which identifies countries that do not adequately and effectively protect intellectual property rights. Canada remains on the Special 301 Watch List in 2015. The IIPA has noted that Canada's regime does not adequately address the issue of copyright infringement.

In the context of Canada's ongoing international trade negotiations, there may be a move toward strengthening Canada's copyright law against online infringers.

3. Unsettling: The Competition Bureau's Review of Pharma Agreements

In September 2014, the Competition Bureau published the white paper "Patent Litigation Settlement Agreements: A Canadian Perspective". It documents the Bureau's interest in preventing patent litigation settlement agreements such as, "pay-for-delay" or "reverse payment" settlements between brand name and generic pharmaceutical manufacturers that would improperly delay generic entry into the Canadian market. The Bureau views such settlements as more than a mere exercise of a patent right, and potentially reviewable under the civil and criminal provisions of the Competition Act.

The release of the white paper reminds the industry that IP owners must be alert to Canadian competition issues when entering into settlement agreements involving their intellectual property rights. Given the Competition Bureau's greater interest in intellectual property settlements, we anticipate competition issues will increasingly be a focus when negotiating settlement agreements.

4. Bio-dominance: Blurred Lines and the New Wave of Pharma Litigation

In recent years, patents covering many major small-drug molecule pharmaceuticals have expired. Pharmaceutical companies prepared and responded by diversifying their portfolios and developing new products, such as biologics and biosimilars or, as they are known in Canada, subsequent entry biologics (SEBs). As a result, we anticipate a rise in litigation over these products.

A biologic is a protein-based therapy that is derived from, or produced using, a living organism. Biologics are used to treat a range of conditions and diseases such as cancer, rheumatoid arthritis, rare blood disorders, multiple sclerosis, diabetes and HIV/AIDS. While biologic drugs are in frequent use in Canada, they have seldom been the subject of patent litigation.

The only case in the last 15 years litigated to a decision (now vacated, and never to be heard again) is Abbvie Corp v Janssen Inc, 2014 FC 55 rev'd 2014 FCA 242. Abbvie owns a patent pertaining to human antibodies and their use in treating autoimmune diseases. Janssen produces a human monoclonal antibody marketed in Canada to treat psoriasis symptoms. The Trial Judge found that Abbott's patent was valid and infringed by Janssen's product. This decision was overturned by the Federal Court of Appeal and returned to the Trial Judge for a new decision. While this matter has settled out of court and no further decision on the merits will be released, it remains the harbinger of the future of pharmaceutical litigation.

The decision in Abbvie v Janssen also exemplifies the blurring of the traditional distinction between brand and generic manufacturers in biologics litigation. This phenomenon is also observed in the context of SEBs. SEBs are biologic drugs that enter the Canadian market with a demonstrated similarity to a reference biologic drug. Manufacturers of SEBs are considered second persons under the Patented Medicines (Notice of Compliance) Regulations. However, SEBs are not considered identical to biologic drugs and submissions to Health Canada for SEBs are akin to new drug submissions, requiring more detailed information than is typically required for small-molecule generics.

As a number of patents covering biologic drugs are set to expire in the next few years, we anticipate an increase in litigation over biologics in Canada.

5. Ramped-up Pricing Review by the Patented Medicines Prices Review Board

On January 22, 2015, the Patented Medicines Prices Review Board (PMPRB) issued a Notice of Hearing alleging Alexion Pharmaceuticals Inc. excessively priced its patented medicine Soliris (eculizumab) in Canada. Soliris (eculizumab), a biologic, is the first and only treatment for patients with Paroxysmal Nocturnal Hemoglobia (PNH), a rare and life-threatening blood disorder, and Atypical Hemolytic Uremic Syndrome (aHUS), a rare and life-threatening genetic disorder. The PMPRB alleges that the annual cost of treatment for this drug in Canada is excessive and higher than in the United States, France, Germany, Italy, Sweden, Switzerland and the United Kingdom. Alexion refutes all of the allegations in their entirety.

A decision in this case will be noteworthy. This is the first case initiated by the PMPRB since 2012 alleging excessive pricing of a patented medicine. If a board adjudication panel finds the price is excessive at a hearing to be held no later than March 6, 2015, it could order that the cost of Soliris (eculizumab) be reduced and that Alexion repay a surplus income.


As IP law protects innovation and creativity, it should evolve with the times. In 2015, it may do so at an accelerated rate. While it is impossible to predict precisely how all will unfold, 2015 is trending toward an eventful year.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.